Zsírmáj (MASLD/MASH): vizsgálatok itt: Belgium
16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Anderlecht, Edegem, Genk, Gent, Leuven, Liège, Namur, Roeselare, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 1800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - 3. fázisTaking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Anderlecht, Edegem, Genk, Liège
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - 3. fázisTaking peopleA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Where
- Anderlecht, Edegem, Gent
- Életkor
- 18 év and over
- People
- 205 worldwide
- Run by
- Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 · EU 2024-512895-36-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Anderlecht, Brussels, Edegem, Genk, Gent, Jette
- Életkor
- 18 év to 80 év
- People
- 1350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Where
- Anderlecht, Edegem, Genk, Gent, Jette, Roeselare, Sint-Lambrechts-Woluwe
- Életkor
- 18 év to 75 év
- People
- 1800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00 - 3. fázisNot yet taking people in BelgiumA pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
- Where
- Anderlecht, Edegem, Gent, Liège, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 382 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 · EU 2026-525755-82-00 - 3. fázisNot yet taking people in BelgiumA study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
- Where
- Anderlecht, Edegem, Gent, Liège, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 69 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 · EU 2026-525757-37-00 - 3. fázisTaking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Brussels, Edegem, Ghent, Kortrijk, Ostend, Roeselare, Sint-Niklaas
- Életkor
- 18 év and over
- People
- 4500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - 3. fázisTaking peopleA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- Where
- Anderlecht, Edegem, Gent, Liège, Sint-Lambrechts-Woluwe
- Életkor
- 18 év to 75 év
- People
- 1250 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00 - No phaseTaking peopleTargeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
- Where
- Brussels, Louvain-la-Neuve
- Életkor
- 18 év to 70 év
- People
- 60
- Run by
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
See details and how to joinNCT06506513 - 1. fázisTaking peopleA Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Where
- Edegem
- Életkor
- 18 év to 65 év
- People
- 124
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06575400 - No phaseTaking peoplePrevalence of NAFLD in T1DM Patients
- Where
- Genk
- Életkor
- 18 év and over
- People
- 138
- Run by
- Ziekenhuis Oost-Limburg
See details and how to joinNCT06445361 - No phaseTaking peoplePrevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
- Where
- Brussels
- Életkor
- 18 év and over
- People
- 150
- Run by
- Centre Hospitalier Universitaire Saint Pierre
See details and how to joinNCT06814600 - No phaseTaking peopleGlobal Research Initiative for Patients Screening on MASH
- Where
- Antwerp, Brussels
- Életkor
- 18 év to 75 év
- People
- 10 000 worldwide
- Run by
- Julius Clinical
See details and how to joinNCT05651724 - No phaseTaking peopleComparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
- Where
- De Haan, Ghent
- Életkor
- 8 év to 18 év
- People
- 850
- Run by
- University Hospital, Ghent
See details and how to joinNCT05309863 - No phaseTaking peopleThe European NAFLD Registry
- Where
- Antwerp
- Életkor
- 18 év to 100 év
- People
- 10 000 worldwide
- Run by
- Newcastle University
See details and how to joinNCT04442334